Fertility preservation in patients with cancer: ASCO clinical practice guideline update

Journal of Clinical Oncology

Volumn 36, Issue 19, 2018, Pages 1994-2001

  Oktay, Kutluk ^a   Harvey, Brittany E ^b   Partridge, Ann H ^c   Quinn, Gwendolyn P ^d   Reinecke, Joyce ^e   Taylor, Hugh S ^a   Hamish Wallace, W ^g   Wang, Erica T ^f   Loren, Alison W ^h  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b AMERICAN SOCIETY OF CLINICAL ONCOLOGY   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Alliance for Fertility Preservation   (United States)

^f CEDARS SINAI MEDICAL CENTER   (United States)

^g Hospital for Sick Children   (United Kingdom)

^h UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; GONADORELIN AGONIST;

ARTICLE; BREAST CANCER; CANCER PATIENT; CRYOPRESERVATION; EMBRYO; FEMALE; FERTILITY PRESERVATION; HEALTH CARE PERSONNEL; HUMAN; MALIGNANT NEOPLASM; META ANALYSIS; OVARY INSUFFICIENCY; OVARY TISSUE; PATIENT EDUCATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; SPERM PRESERVATION; SYSTEMATIC REVIEW; TISSUE PRESERVATION; TISSUE TRANSPLANTATION; ADULT; CHILD; MALE; NEOPLASM; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ADULT; CHILD; FEMALE; FERTILITY PRESERVATION; HUMANS; MALE; NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 85049098411     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2018.78.1914     Document Type: Article

References (35)

1. Loren AW, Mangu PB, Beck LN, et al: Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 31:2500-2510, 2013
2. Shojania KG, Sampson M, Ansari MT, et al: How quickly do systematic reviews go out of date? A survival analysis. Ann Intern Med 147:224-233, 2007
3. Gerber B, von Minckwitz G, Stehle H, et al: Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: The GBG 37 ZORO study. J Clin Oncol 29:2334-2341, 2011
4. Munster PN, Moore AP, Ismail-Khan R, et al: Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer. J Clin Oncol 30:533-538, 2012
5. Elgindy EA, El-Haieg DO, Khorshid OM, et al: Gonadatrophin suppression to prevent chemotherapy-induced ovarian damage: A randomized controlled trial. Obstet Gynecol 121:78-86, 2013
6. Lambertini M, Boni L, Michelotti A, et al: Ovarian suppression with triptorelin during adjuvant breast cancer chemotherapy and long-term ovarian function, pregnancies, and disease-free survival: A randomized clinical trial. JAMA 314:2632-2640, 2015
7. Moore HC, Unger JM, Phillips KA, et al: Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med 372:923-932, 2015
8. Demeestere I, Brice P, Peccatori FA, et al: No evidence for the benefit of gonadotropin-releasing hormone agonist in preserving ovarian function and fertility in lymphoma survivors treated with chemotherapy: Final long-term report of a prospective randomized trial. J Clin Oncol 34:2568-2574, 2016
9. Leonard RCF, Adamson DJA, Bertelli G, et al: GnRH agonist for protection against ovarian toxicity during chemotherapy for early breast cancer: The Anglo Celtic Group OPTION trial. Ann Oncol 28:1811-1816, 2017
10. Turner NH, Partridge A, Sanna G, et al: Utility of gonadotropin-releasing hormone agonists for fertility preservation in young breast cancer patients: The benefit remains uncertain. Ann Oncol 24:2224-2235, 2013
11. Elgindy E, Sibai H, Abdelghani A, et al: Protecting ovaries during chemotherapy through gonad suppression: A systematic review and meta-analysis. Obstet Gynecol 126:187-195, 2015
12. Lambertini M, Ceppi M, Poggio F, et al: Ovarian suppression using luteinizing hormone-releasing hormone agonists during chemotherapy to preserve ovarian function and fertility of breast cancer patients: A meta-analysis of randomized studies. Ann Oncol 26:2408-2419, 2015
13. Munhoz RR, Pereira AA, Sasse AD, et al: Gonadotropin-releasing hormone agonists for ovarian function preservation in premenopausal women undergoing chemotherapy for early-stage breast cancer: A systematic review and meta-analysis. JAMA Oncol 2:65-73, 2016
14. Lambertini M, Moore HCF, Leonard RCF, et al: Pooled analysis of five randomized trials investigating temporary ovarian suppression with gonadotropin-releasing hormone analogs during chemotherapy as a strategy to preserve ovarian function and fertility in premenopausal early breast cancer patients. Presented at San Antonio Breast Cancer Symposium, San Antonio, Texas, December 5-9, 2017
15. Lambertini M, Cinquini M, Moschetti I, et al: Temporary ovarian suppression during chemotherapy to preserve ovarian function and fertility in breast cancer patients: A GRADE approach for evidence evaluation and recommendations by the Italian Association of Medical Oncology. Eur J Cancer 71: 25-33, 2017
16. Muñoz M, Santaballa A, Seguí MA, et al: SEOM Clinical Guideline of fertility preservation and reproduction in cancer patients (2016). Clin Transl Oncol 18:1229-1236, 2016
17. Paluch-Shimon S, Pagani O, Partridge AH, et al: Second international consensus guidelines for breast cancer in young women (BCY2). Breast 26: 87-99, 2016
18. Coates AS, Winer EP, Goldhirsch A, et al: Tailoring therapies–Improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol 26:1533-1546, 2015
19. Peccatori FA, Azim HA Jr, Orecchia R, et al: Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 24:vi160-vi170, 2013 (suppl 6)
20. National Comprehensive Cancer Network: National Comprehensive Cancer Network Guidelines - Adolescent and Young Adult (AYA) Oncology. 2017. https://www.nccn.org/professionals/physician_gls/pdf/aya.pdf
21. National Comprehensive Cancer Network: National Comprehensive Cancer Network Guidelines - Breast Cancer. 2017. https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf
22. Demeestere I, Brice P, Peccatori FA, et al: Gonadotropin-releasing hormone agonist for the prevention of chemotherapy-induced ovarian failure in patients with lymphoma: 1-year follow-up of a prospective randomized trial. J Clin Oncol 31:903-909, 2013
23. Pacheco F, Oktay K: Current success and efficiency of autologous ovarian transplantation: A meta-analysis. Reprod Sci 24:1111-1120, 2017
24. Meirow D, Ra’anani H, Shapira M, et al: Transplantations of frozen-thawed ovarian tissue demonstrate high reproductive performance and the need to revise restrictive criteria. Fertil Steril 106: 467-474, 2016
25. Jadoul P, Guilmain A, Squifflet J, et al: Efficacy of ovarian tissue cryopreservation for fertility preservation: Lessons learned from 545 cases. Hum Reprod 32:1046-1054, 2017
26. U.S. Cancer Statistics Working Group: United States cancer statistics: 1999–2012 Incidence and mortality web-based report. Atlanta: U.S. Department of Health and Human Services. Atlanta, Centers for Disease Control and Prevention and National Cancer Institute, 2015. www.cdc.gov/uscs
27. Howlader N, Noone AM, Krapcho M, et al: SEER Cancer Statistics Review, 1975-2013. Bethesda, MD, National Cancer Institute, 2016.
28. Mead H, Cartwright-Smith L, Jones K, et al: Racial and Ethnic Disparities in U.S. Health Care: A Chartbook. The Commonwealth Fund, New York, NY, 2008
29. American Cancer Society: Cancer facts and figures for African Americans 2016-2018. Atlanta, GA, American Cancer Society, 2016.
30. Gilligan T, Coyle N, Frankel RM, et al: Patient-clinician communication: American Society of Clinical Oncology consensus guideline. J Clin Oncol 35: 3618-3632, 2017
31. Schnipper LE, Davidson NE, Wollins DS, et al: American Society of Clinical Oncology statement: A conceptual framework to assess the value of cancer treatment options. J Clin Oncol 33:2563-2577, 2015
32. Schnipper LE, Davidson NE, Wollins DS, et al: Updating the American Society of Clinical Oncology Value framework: Revisions and reflections in response to comments received. J Clin Oncol 34: 2925-2934, 2016
33. Streeter SB, Schwartzberg L, Husain N, et al: Patient and plan characteristics affecting abandonment of oral oncolytic prescriptions. J Oncol Pract 746s-51s, 2011 (suppl)
34. Dusetzina SB, Winn AN, Abel GA, et al: Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia. J Clin Oncol 32:306-311, 2014
35. Meropol NJ, Schrag D, Smith TJ, et al: American Society of Clinical Oncology guidance statement: The cost of cancer care. J Clin Oncol 27:3868-3874, 2009